- Home
- CCCC vs GNLX Comparison
CCCC vs GNLX Comparison
Compare CCCC & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- GNLX
- Stock Information
- Founded
- CCCC 2015
- GNLX 2001
- Country
- CCCC United States
- GNLX United States
- Employees
- CCCC N/A
- GNLX N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CCCC Health Care
- GNLX Health Care
- Exchange
- CCCC Nasdaq
- GNLX Nasdaq
- Market Cap
- CCCC 242.3M
- GNLX 202.4M
- IPO Year
- CCCC 2020
- GNLX 2023
- Fundamental
- Price
- CCCC $2.44
- GNLX $4.88
- Analyst Decision
- CCCC Strong Buy
- GNLX Strong Buy
- Analyst Count
- CCCC 4
- GNLX 4
- Target Price
- CCCC $8.50
- GNLX $19.75
- AVG Volume (30 Days)
- CCCC 1.5M
- GNLX 325.2K
- Earning Date
- CCCC 11-06-2025
- GNLX 11-05-2025
- Dividend Yield
- CCCC N/A
- GNLX N/A
- EPS Growth
- CCCC N/A
- GNLX N/A
- EPS
- CCCC N/A
- GNLX N/A
- Revenue
- CCCC $30,108,000.00
- GNLX N/A
- Revenue This Year
- CCCC N/A
- GNLX N/A
- Revenue Next Year
- CCCC N/A
- GNLX N/A
- P/E Ratio
- CCCC N/A
- GNLX N/A
- Revenue Growth
- CCCC N/A
- GNLX N/A
- 52 Week Low
- CCCC $1.09
- GNLX $1.99
- 52 Week High
- CCCC $5.10
- GNLX $8.54
- Technical
- Relative Strength Index (RSI)
- CCCC 49.92
- GNLX 39.39
- Support Level
- CCCC $2.39
- GNLX $4.81
- Resistance Level
- CCCC $2.63
- GNLX $5.28
- Average True Range (ATR)
- CCCC 0.16
- GNLX 0.77
- MACD
- CCCC -0.00
- GNLX -0.27
- Stochastic Oscillator
- CCCC 57.63
- GNLX 14.21
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.